Modulation of autophagy with hydroxychloroquine in patients with advanced non-small cell lung cancer (NSCLC): A phase Ib study.

Jyoti Malhotra, Salma K. Jabbour, Michelle Orlick, Gregory Riedlinger, Sonali Joshi, Jessie Yanxiang Guo, Eileen White, Joseph Aisner

Journal of Clinical Oncology · 2018 · 14 citations · 0 references

Concepts

Abstract

e21138 Background: A potential resistance mechanism to chemotherapy in NSCLC is through activation of cell survival pathways such as autophagy. Studies in genetically engineered mouse models demonstrate that autophagy inhibition suppresses lung tumor development and progression, especially in Kras mutated tumors. We report safety and efficacy of adding an autophagy inhibitor, hydroxychloroquine (HCQ) to front-line platinum-based chemotherapy in a phase Ib single arm study in patients with metastatic NSCLC. Methods: Patients with newly diagnosed metastatic NSCLC were treated with carboplatin, paclitaxel (and bevacizumab if meeting criteria) and HCQ 200 to 600 mg BID for the escalation part and 600 mg BID for the expansion. Patients continued on HCQ (+/- bevacizumab) maintenance after 4-6 cycles of therapy. Results: Of the 40 patients enrolled (8 on escalation; 32 on expansion), 58% were male; 31% had squamous histology. Median age was 62 years. Sixteen patients (40%) had at least one grade 3 or higher treatment-related adverse event with the most common being neutropenia (35%), anemia (15%), thrombocytopenia (10%) and dehydration (10%). The objective response rate (ORR) was 47% in the 34 patients evaluable for response. Additionally, 21% patients demonstrated stable disease for a total clinical benefit rate of 68%. The median PFS was 3.7 months (95% CI 3.2 to 5.8 months). Patients with non-squamous histology had a higher ORR (52% vs. 33%) and improved PFS compared to those with squamous histology (4.7 vs. 2.3 months). Twenty-one of the 40 patients' tumors were assessed for Kras mutations; 9 of the 21 tumors were Kras mutated. The ORR according to Kras was 44% for mutated and 42% for wild-type: PFS was 3.7 vs. 2.8 months. Conclusions: Addition of HCQ has a similar toxicity profile compared to chemotherapy alone. The response rate to therapy in Kras mutated and wild type tumors was similar; even though Kras mutated tumors usually demonstrate worse responses and PFS to chemotherapy. Autophagy inhibition may help overcome chemotherapy resistance in patients with non-squamous NSCLC especially if Kras mutated. Further study with autophagy inhibiton in a more selected population appears warranted. Clinical trial information: NCT01649947, NCT00728845.